Cardiff Oncology, Inc.
NASDAQ:CRDF · NASDAQ Capital Market
+$0.03 today
Vol 0.93M · Avg 1.05M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:CRDF · Revenue to Net Income
Key Ratios
Analysis
$525.0K of revenue converted into -$44.8M of net income for the selected period. Gross margin is -2292.6% and net margin is -13496.0%, showing how much revenue survives after costs and taxes. EPS is $-0.67, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $593.0K -13.2% | $683.0K +40.0% | $488.0K +26.4% | $386.0K +7.5% | $359.0K | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 | $725.6M | $804.0M | $882.4M |
| Gross Profit | $593.0K -13.2% | $683.0K +40.0% | $488.0K +26.4% | $386.0K +7.5% | $359.0K | $8.9B | $7.6B | $6.2B |
| Gross Margin | 100.0% +0.0pp | 100.0% +0.0pp | 100.0% +0.0pp | 100.0% +0.0pp | 100.0% | 9.8% | 28.9% | 38.3% |
| Research & Development | $35.3M -4.1% | $36.9M +12.2% | $32.9M +21.2% | $27.1M +56.0% | $17.4M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $14.2M +14.0% | $12.5M -4.3% | $13.0M -1.0% | $13.2M +11.3% | $11.8M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $49.6M +0.4% | $49.3M +7.5% | $45.9M +13.9% | $40.3M +37.9% | $29.2M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $904.0K +123.8% | $404.0K +1.5% | $398.0K +68.6% | $236.0K -47.7% | $451.0K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$44.9M +0.2% | -$45.0M -9.7% | -$41.0M -6.7% | -$38.5M -38.2% | -$27.8M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -7579.6% -987.1pp | -6592.5% +1817.9pp | -8410.5% +1555.4pp | -9965.8% -2210.9pp | -7754.9% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$49.0M -0.6% | -$48.7M -7.1% | -$45.4M -13.8% | -$39.9M -38.3% | -$28.9M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -8256.3% -1133.2pp | -7123.1% +2182.6pp | -9305.7% +1031.6pp | -10337.3% -2299.7pp | -8037.6% | 16.6% | 24.1% | 22.0% |
| Interest Income | $3.1M -4.8% | $3.3M -19.9% | $4.1M +157.4% | $1.6M +498.9% | $264.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $3.1M -3.4% | $3.2M -18.9% | $4.0M +231.5% | $1.2M +112.4% | $564.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$45.9M -0.9% | -$45.4M -9.6% | -$41.4M -7.1% | -$38.7M -36.8% | -$28.3M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -7732.0% -1080.4pp | -6651.7% +1840.3pp | -8492.0% +1534.9pp | -10026.9% -2146.4pp | -7880.5% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$45.9M -0.9% | -$45.4M -9.6% | -$41.4M -7.1% | -$38.7M -36.8% | -$28.3M | $4.9B | $4.8B | $4.7B |
| Net Margin | -7732.0% -1080.4pp | -6651.7% +1840.3pp | -8492.0% +1534.9pp | -10026.9% -2146.4pp | -7880.5% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$1 +27.4% | -$1 -2.2% | -$1 -4.5% | -$1 -21.9% | -$1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$1 +27.4% | -$1 -2.2% | -$1 -4.5% | -$1 -21.9% | -$1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $66.8M +40.3% | $47.6M +6.7% | $44.7M +2.5% | $43.6M +11.7% | $39.0M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $66.8M +40.3% | $47.6M +6.7% | $44.7M +2.5% | $43.6M +11.7% | $39.0M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Forte Biosciences, Inc.
NASDAQ:FBRX
$248.90M
Innate Pharma S.A.
NASDAQ:IPHA
$170.34M
Molecular Partners AG
NASDAQ:MOLN
$147.61M
PepGen Inc.
NASDAQ:PEPG
$123.81M
Milestone Pharmaceuticals Inc.
NASDAQ:MIST
$112.51M
Corbus Pharmaceuticals Holdings, Inc.
NASDAQ:CRBP
$103.10M
Elicio Therapeutics, Inc.
NASDAQ:ELTX
$72.53M
Cassava Sciences, Inc.
SAVA
$63.77M
Rani Therapeutics Holdings, Inc.
NASDAQ:RANI
$50.69M
Applied Therapeutics, Inc.
APLT
$14.86M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does CRDF generate?
Cardiff Oncology, Inc. (CRDF) reported $593,000.00 of revenue in fiscal 2025.
Is CRDF profitable?
Cardiff Oncology, Inc. (CRDF) reported -$45,851,000.00 of net income, with a net margin of -7732.0%.
Explore More
Continue the stock analysis
Jump to another research area for this company.